Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Novo Nordisk (NVO) shares rallied more than 6% today after the Food and Drug Administration (FDA) approved Wegovy for ...

Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

Investors eyed risks around a high-stakes US-Ukraine meeting, kicking off a week dominated by a Federal Reserve speech that ...

Shares in Danish pharma company Novo Nordisk jumped after it halved the out-of-pocket price of Ozempic in the US and gained ...